GRI Bio Inc. (GRI) - Total Assets
Based on the latest financial reports, GRI Bio Inc. (GRI) holds total assets worth $11.34 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check GRI cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GRI Bio Inc. - Total Assets Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s total assets have evolved over time, based on quarterly financial data. Check GRI cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
GRI Bio Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
GRI Bio Inc.'s total assets of $11.34 Million consist of 99.2% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GRI company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GRI Bio Inc.'s current assets represent 99.2% of total assets in 2025, a decrease from 99.8% in 2018.
- Cash Position: Cash and equivalents constituted 95.0% of total assets in 2025, down from 95.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GRI Bio Inc. Competitors by Total Assets
Key competitors of GRI Bio Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
GRI Bio Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.21 | 1.41 | 6.82 |
| Quick Ratio | 14.21 | 1.41 | 6.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.48 Million | $1.15 Million | $9.73 Million |
GRI Bio Inc. - Advanced Valuation Insights
This section examines the relationship between GRI Bio Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.39 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 51.0% |
| Total Assets | $8.67 Million |
| Market Capitalization | $3.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values GRI Bio Inc.'s assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: GRI Bio Inc.'s assets grew by 51.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GRI Bio Inc. (2018–2025)
The table below shows the annual total assets of GRI Bio Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.67 Million | +51.00% |
| 2024-12-31 | $5.74 Million | +94.15% |
| 2023-12-31 | $2.96 Million | +671.80% |
| 2022-12-31 | $383.00K | +75.69% |
| 2021-12-31 | $218.00K | -77.17% |
| 2020-12-31 | $955.00K | -77.66% |
| 2019-12-31 | $4.28 Million | +568.87% |
| 2018-12-31 | $639.23K | -- |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more